SRPT INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=1306 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 16, 2023, after market hours, the Company issued a press release which "announced that at its late cycle meeting for the SRP–9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration's Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP–9001 in advance of the May 29, 2023 regulatory action date."

As explained by the Investor's Business Daily in an article entitled "Sarepta Crashes on an Unexpected Roadblock for Its Gene Therapy", the Food and Drug Administration's decision was a surprise. The article quoted a UBS analyst as saying that "given the announcement of the advisory committee decision, against a backdrop of the Office of Therapeutics communicating how capacity constrained it is at every public appearance, we do see a potential risk of (approval date) extension."

On this news, the price of Sarepta's stock fell $26.98, or 18%, to close at $122.69 per share on March 17, 2023, the next trading day.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796427)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Dutch Bros, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – BROS

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Dutch Bros, Inc. (NYSE: BROS) between March 1, 2022 and May 11, 2022, both dates inclusive (the "Class Period"), of the important May 1, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Dutch Bros securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Dutch Bros class action, go to https://rosenlegal.com/submit–form/?case_id=12586 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 1, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) the Company was experiencing increased costs and expenses, including on dairy; (2) as a result, the Company was experiencing increased margin pressure and decreased profitability in the first quarter of 2022; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Dutch Bros class action, go to https://rosenlegal.com/submit–form/?case_id=12586 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796337)

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages PLDT Inc. Investors With Losses to Secure Counsel Before Important April 7 Deadline in Securities Class Action Initiated by the Firm – PHI

NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PLDT Inc. (NYSE: PHI) between January 1, 2019 and December 19, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased PLDT securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PLDT class action, go to https://rosenlegal.com/submit–form/?case_id=10686 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) there were capital spending budget overruns; (2) defendants failed to address weaknesses that allowed such budget overruns; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the PLDT class action, go to https://rosenlegal.com/submit–form/?case_id=10686 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796436)

ROSEN, A TOP RANKED LAW FIRM, Encourages Catalent, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – CTLT

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period"), of the important April 25, 2023, lead plaintiff deadline.

SO WHAT: If you purchased Catalent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Catalent class action, go to https://rosenlegal.com/submit–form/?case_id=12490 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles ("GAAP"); (2) the Company had material weaknesses in its internal control over financial reporting related to revenue recognition; (3) the Company falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (4) the Company disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and (5) as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Company's financial performance, outlook and regulatory compliance during the Class Period. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Catalent class action, go to https://rosenlegal.com/submit–form/?case_id=12490 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796195)

INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Block, Inc. f/k/a Square, Inc. Investors with Losses to Inquire About Class Action Investigation – SQ

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Block, Inc. f/k/a Square, Inc. (NYSE: SQ) resulting from allegations that Block, Inc. may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Block securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=13546 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 23, 2023, before the market opened, market analyst Hindenburg Research released a report entitled "Block: How Inflated User Metrics and "Frictionless" Fraud Facilitation Enabled Insiders to Cash Out Over $1 Billion." Hindenburg's research, which took place over a two–year period and involved "dozens of interviews with former employees, partners, and industry experts, extensive review of regulatory and litigation records" led it to conclude that the "'magic' behind Block's business has not been disruptive innovation, but rather the company's willingness to facilitate fraud against consumers and the government, avoid regulation, dress up predatory loans and fees as revolutionary technology, and mislead investors with inflated metrics." The report further alleged, among other things, that Block had "wildly overstated" its user accounts and provided banking services to violent criminals.

On this news, the price of Block's stock declined by as much as 20% in intraday trading before closing at $61.88 on March 23, 2023, a 14.8% decline from the prior day.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796411)

Nyxoah Raises $3 Million from an At-the-Market Equity Offering

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Raises $3 Million from an At–the–Market Equity Offering

Mont–Saint–Guibert, Belgium "" March 27, 2023, 10:05pm CET / 4:05pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $2.8 million in gross proceeds pursuant to the Company's $50 million at–the–market (“ATM”) program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The shares were purchased by historical Nyxoah shareholder Cochlear Limited, and the proceeds will be used for general corporate purposes.

The ordinary shares described above were sold pursuant to the Company's shelf registration statement on Form F–3 (File No. 333–268955), previously filed with the Securities and Exchange Commission ("SEC") on December 22, 2022, which became effective on January 6, 2023, and a prospectus supplement dated January 6, 2023 and the accompanying prospectus the Company filed with the SEC in connection with the offer and sale of the Company's common stock pursuant to the Controlled Equity OfferingSM Sales Agreement, dated as of December 22, 2022 with Cantor Fizgerald & Co., as sales agent (prospectus@cantor.com).

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

FORWARD–LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2022, filed with the Securities and Exchange Commission ("SEC") on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment


GLOBENEWSWIRE (Distribution ID 1000800476)

Nyxoah Lève 3 Millions de Dollars dans le Cadre d'une Émission d'Actions At-The-Market

INFORMATIONS PRIVILGIES
INFORMATIONS RGLEMENTES

Nyxoah Lve 3 Millions de Dollars dans le Cadre d'une mission d'Actions At–The–Market

Mont–Saint–Guibert, Belgique "" 27 mars 2023, 22h05 CET / 16h05 ET "" Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) ( Nyxoah ou la Socit ) opre dans le secteur des technologies mdicales et se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La Socit a annonc aujourd'hui que la Socit a lev un produit brut de 2,8 millions de dollars dans le cadre de son programme de 50 millions de dollars At–The–Market (“ATM”) tabli le 22 dcembre 2022 un prix d'mission gal au prix du march sur le Nasdaq Global Market au moment de la vente. Les actions ont t achetes par Cochlear Limited, actionnaire historique de Nyxoah, et le produit sera utilis des fins gnrales.

Les actions ordinaires dcrites ci–dessus ont t vendues conformment la dclaration d'enregistrement pralable de la Socit sur le formulaire F–3 (dossier n . 333–268955), prcdemment dpose auprs de la Securities and Exchange Commission (“SEC”) le 22 dcembre 2022, qui est entre en vigueur le 6 janvier 2023, et d'un supplment de prospectus dat du 6 janvier 2023 et du prospectus d'accompagnement que la Socit a dpos auprs de la SEC dans le cadre de l'offre et de la vente des actions ordinaires de la Socit conformment l'accord de vente Controlled Equity OfferingSM, dat du 22 dcembre 2022 et conclu avec Cantor Fizgerald & Co, en tant qu'agent de vente (prospectus@cantor.com).

propos de Nyxoah
Nyxoah opre dans le secteur des technologies mdicales. Elle se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le systme Genio , une thrapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reu le marquage CE, centre sur le patient et destine traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associ un risque accru de mortalit et des comorbidits, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits rparatrices et vivre pleinement leur vie.

la suite de la finalisation probante de l'tude BLAST OSA, le systme Genio a reu le marquage europen CE en 2019. Nyxoah a ralis avec succs deux IPO : l'une sur Euronext Bruxelles en septembre 2020 et l'autre sur le NASDAQ en juillet 2021. Grce aux rsultats positifs de l'tude BETTER SLEEP, Nyxoah a reu le marquage CE pour l'extension de ses indications thrapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thrapies concurrentes sont actuellement contre–indiques. En outre, la Socit mne actuellement l'tude pivot IDE DREAM pour la FDA obtenir l'autorisation de mise sur le march.

Attention "" marquage CE depuis 2019. Dispositif de recherche aux tats–Unis. Limit un usage exprimental aux tats–Unis par la loi fdrale amricaine.

DCLARATIONS PROSPECTIVES

Certaines dclarations, croyances et opinions contenues dans le prsent communiqu de presse sont de nature prospective et refltent les attentes actuelles de la socit ou, le cas chant, des administrateurs ou de la direction de la socit concernant le systme Genio , les tudes cliniques prvues et en cours sur le systme Genio , les avantages potentiels du systme Genio ; les objectifs de Nyxoah en ce qui concerne le dveloppement, la voie rglementaire et l'utilisation potentielle du systme Genio ; l'utilit des donnes cliniques pour l'obtention ventuelle de l'approbation du systme Genio par la FDA ; et les rsultats d'exploitation, la situation financire, les liquidits, les performances, les perspectives, la croissance et les stratgies de la socit. De par leur nature, les dclarations prvisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothses et d'autres facteurs qui pourraient faire en sorte que les rsultats ou vnements rels diffrent matriellement de ceux exprims ou sous–entendus dans les dclarations prvisionnelles. Ces risques, incertitudes, hypothses et facteurs pourraient avoir une incidence ngative sur les rsultats et les effets financiers des plans et des vnements dcrits dans le prsent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes noncs dans la section “Facteurs de risque” du rapport annuel de la socit sur le formulaire 20–F pour l'exercice clos le 31 dcembre 2022, dpos auprs de la Securities and Exchange Commission (“SEC”) le 22 mars 2023, et des rapports ultrieurs que la socit dpose auprs de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les vnements, les performances ou les rsultats rels diffrent de manire significative de tout dveloppement anticip. Les dclarations prospectives contenues dans le prsent communiqu de presse concernant des tendances ou des activits passes ne constituent pas des garanties de performances futures et ne doivent pas tre considres comme une dclaration selon laquelle ces tendances ou activits se poursuivront l'avenir. En outre, mme si les rsultats ou dveloppements rels sont conformes aux dclarations prospectives contenues dans le prsent communiqu de presse, ces rsultats ou dveloppements peuvent ne pas tre reprsentatifs des rsultats ou dveloppements des priodes futures. Aucune dclaration ou garantie n'est donne quant l'exactitude ou la justesse de ces dclarations prospectives. En consquence, la socit dcline expressment toute obligation ou tout engagement de publier des mises jour ou des rvisions des dclarations prospectives contenues dans le prsent communiqu de presse la suite d'un changement des attentes ou d'un changement des vnements, conditions, hypothses ou circonstances sur lesquels ces dclarations prospectives sont bases, sauf si la loi ou la rglementation l'exige expressment. Ni la Socit, ni ses conseillers ou reprsentants, ni aucune de ses filiales, ni les dirigeants ou employs de ces personnes ne garantissent que les hypothses sous–jacentes ces dclarations prospectives sont exemptes d'erreurs et n'acceptent aucune responsabilit quant l'exactitude future des dclarations prospectives contenues dans ce communiqu de presse ou quant la survenance effective des dveloppements prvus. Vous ne devriez pas accorder une confiance excessive aux dclarations prospectives, qui ne sont valables qu' la date du prsent communiqu de presse.

Contacts :
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Pice jointe


GLOBENEWSWIRE (Distribution ID 1000800476)

ROSEN, A LEADING LAW FIRM, Encourages BlockFi Interest Account Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Against Zac Prince, Flori Marquez, Amit Cheela, David Olsson, and Samia Bayou

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds investors in BlockFi Interest Accounts ("BIAs") between March 4, 2019 and November 28, 2022, inclusive (the "Class Period"), against Zac Prince, Flori Marquez, Amit Cheela, David Olsson, and Samia Bayou (together, "Defendants"), of the important May 1, 2023 lead plaintiff deadline.

SO WHAT: If you invested in BlockFi Interest Accounts ("BIAs") during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the BlockFi class action, go to https://rosenlegal.com/submit–form/?case_id=12656 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 1, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Defendants made false and misleading statements to promote BlockFi Interest Accounts ("BIAs"), including that BIAs were a secure method of collecting interest. In addition, the Complaint alleges, among other things, that the defendants omitted and concealed material information concerning the risks associated with BIAs, including through BlockFi's exposure to FTX Trading, Ltd. ("FTX") and Sam Bankman–Fried's trading firm Alameda Research ("Alameda"), both of which collapsed in the wake of revelations that FTX and Alameda were engaging in fraud on a massive scale. In the wake of the FTX collapse, the lawsuit alleges that BlockFi froze withdrawals in BIAs, harming BIA investors. Further, investors in BIAs were not aware of conflicts of interest and self–dealing between BlockFi and other entities, such as Gemini Trust LLC, controlled by Tyler and Cameron Winklevoss. The Complaint further alleges BlockFi and the Individual Defendants engaged in the unlawful offer and sale of securities in violation of Sections 5, 11, 12(a)(2), and 15 of the Securities Act of 1933 by selling BIAs to investors. The lawsuit also alleges claims for violation of Section 10(b) and 20 of the Securities Exchange Act of 1934 and Massachusetts General Law Chapter 110A.

To join the BlockFi class action, go to https://rosenlegal.com/submit–form/?case_id=12656 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796190)

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Hesai Group Investors to Inquire About Securities Class Action Investigation – HSAI

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Hesai Group (NASDAQ: HSAI) resulting from allegations that Hesai may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Hesai securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=13347 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 16, 2023, Hesai announced in a press release its unaudited financial results for the three months and full year ended December 31, 2022. The Company failed to disclose in the Restatement that in their fourth quarter ended December 31, 2022 ("4Q2022"), the last completed quarter before the Company's initial public offering ("IPO"), there was "lower in–house plant capacity utilization rate", which caused the increased shipments of lower–margin advanced driver assistance systems ("ADAS") and light detection and ranging ("LiDAR") products. Loss from operations widened by 84.9% in 4Q2022 compared to their fourth quarter ended in December 31, 2021.

On this news, Hesai's share price fell $1.55, or 10%, to close at $13.69 per share on March 16, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796370)

ROSEN, SKILLED INVESTOR COUNSEL, Encourages DraftKings Inc. Investors with Losses to Secure Counsel Before Important Deadline – DKNG

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of non–fungible tokens ("NFTs") of DraftKings Inc. (NASDAQ: DKNG) between August 11, 2021 and the present (the "Class Period") of the important May 8, 2023 lead plaintiff deadline.

SO WHAT: If you purchased DraftKings NFTs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DraftKings class action, go to https://rosenlegal.com/submit–form/?case_id=1807 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 8, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the NFTs were securities for which DraftKings unlawfully failed to file a registration statement; (2) DraftKings ensured that money invested by class members stayed on DraftKings' private and exclusively controlled marketplace, propping up the market for and overall valuation of DraftKings' NFTs; and (3) as a result, investors have suffered significant damages. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DraftKings class action, go to https://rosenlegal.com/submit–form/?case_id=1807 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8796215)